EMA OKs Sublingual Formulation for Opioid Dependence

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

The new buprenorphine formulation is used as a substitution treatment in adults and adolescents 15 years or older who agree to be treated for addiction.
Medscape Medical News